Favipiravir, single-dose pharmacokinetics and tolerability in volunteers.

Trial Profile

Favipiravir, single-dose pharmacokinetics and tolerability in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Sep 2011

At a glance

  • Drugs Favipiravir (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Toyama Chemical
  • Most Recent Events

    • 17 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
    • 21 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top